The US plans to liberalize competition in the nephropathy treatment market, and the two major dialysis leaders, Davita and Fresenius Medical, rapidly weakened.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.